Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study
Authors:
- Mario SalviMSMario Salvi
- Guia VannucchiGVGuia Vannucchi
- Irene CampiICIrene Campi
- Nicola CurròNCNicola Currò
- Davide DazziDDDavide Dazzi
- Simona SimonettaSSSimona Simonetta
- Paola BonaraPBPaola Bonara
- Stefania RossiSRStefania Rossi
- Clara SinaCSClara Sina
- Claudio GuastellaCGClaudio Guastella
- Roberto RatigliaRRRoberto Ratiglia
- Paolo Beck-PeccozPBPaolo Beck-Peccoz
- 1 January 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 156 (1) , 33-40
Abstract
Introduction: Hyperthyroid Graves’ disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO). Methods: Nine patients with GD, (seven with active TAO, two with mild lid signs) were studied. The trial was only approved as an open pilot study; thus we compared the effect of RTX therapy to that of i.v. glucocorticoids (IVGC) in 20 consecutive patients. Patients were treated with RTX (1000 mg i.v. twice at 2-week interval) or with IVGC (500 mg i.v. for 16 weeks). TAO was assessed by the clinical activity score (CAS) and severity was classified using NOSPECS (No signs or symptoms; Only signs (lid); Soft tissue involvement; Proptosis, Extraocular muscle involvement; Corneal involvement; Sight loss). Thyroid function and lymphocyte count were measured by standardized methods. Results: All patients attained peripheral B-cell depletion with the first RTX infusion. Minor side effects were reported in three patients. Thyroid function was not affected by RTX therapy and hyperthyroid patients required therapy with methimazole. After RTX, the changes in the levels of thyroglobulin antibodies, thyroperoxidase antibodies and TRAb were neither significant nor correlated with CD20+ depletion (P = NS). CAS values before RTX were 4.7 ± 0.5 and decreased to 1.8 ± 0.8 at the end of follow-up (P < 0.0001) and more significantly compared with IVGC (P < 0.05). Proptosis decreased significantly after RTX both in patients with active TAO (ANOVA; P < 0.0001) and those with lid signs (ANOVA; P < 0.003). The degree of inflammation (class 2) decreased significantly in response to RTX (ANOVA; P < 0.001). Relapse of active TAO was not observed in patients treated with RTX, but occurred in 10% of those treated with IVGC, who also experienced adverse effects more frequently (45 vs 33% of patients). Conclusions: RTX positively affects the clinical course of TAO, independently of either thyroid function or circulating antithyroid antibodies, including TRAb. If our findings are confirmed in large controlled studies, RTX may represent a useful therapeutic tool in patients with active TAO.Keywords
This publication has 33 references indexed in Scilit:
- Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves’ Ophthalmopathy and Help to Predict Severity and Outcome of the DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2006
- Effect of High Dose Methylprednisolone Pulse Therapy Followed by Oral Prednisolone Administration on the Production of Anti-TSH Receptor Antibodies and Clinical Outcome in Graves' DiseaseEndocrine Journal, 2005
- Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon?Journal of Endocrinological Investigation, 2004
- Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves’ ophthalmopathy receiving corticosteroid therapyClinical Endocrinology, 2003
- Pathophysiology of Graves’ Ophthalmopathy: The Cycle of DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2003
- Stimulation of Adipogenesis, Peroxisome Proliferator-Activated Receptor- (PPAR ), and Thyrotropin Receptor by PPAR Agonist in Human Orbital Preadipocyte FibroblastsThe Journal of Clinical Endocrinology & Metabolism, 2002
- Thyroid-Infiltrating B Lymphocytes in Graves' Disease are Related to Marginal Zone and Memory B Cell CompartmentsThyroid®, 2001
- Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathyClinical Endocrinology, 2000
- Activation of Human Orbital Fibroblasts through CD40 Engagement Results in a Dramatic Induction of Hyaluronan Synthesis and Prostaglandin Endoperoxide H Synthase-2 ExpressionJournal of Biological Chemistry, 1998
- The Prognostic Value of Thyrotropin Receptor Antibody Measurement in the Early Stages of Treatment of Graves' Disease with Antithyroid DrugsThyroid®, 1998